[Form 4] Xeris Biopharma Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 144 filed for AAR Corp. (NYSE:AIR) discloses a planned insider sale.

• Seller: Eric Pachapa (relationship to issuer not specified).
• Securities: 5,000 common shares.
• Broker: Morgan Stanley Smith Barney LLC.
• Approx. sale date: 04 Aug 2025 on the NYSE.
• Aggregate market value: $364,581.50 (≈ $72.92 per share).
• Total shares outstanding: 35,847,589; proposed sale equals about 0.014 % of outstanding stock.
• Origin of shares: vested restricted stock on 31 Jul 2025.
• Past 3-month activity: seller already disposed of 5,748 shares for $450,142.55.

The filer attests to possessing no undisclosed material adverse information.

Positive

• None.

Negative

• Continued insider selling: 5,000 additional shares filed for sale after 5,748 shares were sold in the prior three months, which some investors may view cautiously.

Insights

Securities Analyst

TL;DR: Small AIR insider sale (0.014 % float); continuation of routine divestitures, limited market impact expected.

The proposed 5,000-share sale, valued at roughly $365k, is immaterial relative to AIR’s 35.8 m shares outstanding. Combined with the recent 5,748-share disposals, the insider will have liquidated ~11,000 shares, still below 0.05 % of float. The shares stem from recent restricted-stock vesting, suggesting ordinary portfolio diversification rather than a signal on fundamentals. No earnings or operational data accompany the filing, and the attestation indicates the insider is unaware of undisclosed negative information. Overall, I view the impact on AIR’s valuation and liquidity as negligible.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McCulloch Kevin

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO IL 60607

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
08/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/01/2025		F		14,651(1)	D	$5.38	1,701,159(2)	D
Common Stock								25,000(3)	I	By Spouse
Common Stock								2,000(3)	I	By Charles R. McCulloch Trust dated 1990

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of August 1, 2025.

2. These shares include 7,225 shares that were purchased on June 30, 2025 due to participation by the reporting individual in the issuer's 2018 Employee Stock Purchase Plan.

3. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

President and Chief Operating Officer

	/s/ Beth Hecht, Attorney-in-Fact	08/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many AAR Corp. (AIR) shares are being sold under this Form 144?

The filing covers 5,000 common shares.

What is the value of the proposed AIR share sale?

The aggregate market value is $364,581.50.

When is the insider planning to sell the AIR shares?

The approximate sale date reported is 04 August 2025.

What percentage of AAR Corp.'s shares does the 5,000-share sale represent?

About 0.014 % of the 35,847,589 shares outstanding.

Has the insider recently sold other AIR shares?

Yes. In the past three months the filer sold 5,748 shares for $450,142.55 in gross proceeds.

How were the shares being sold originally acquired?

They vested as restricted stock on 31 July 2025 under a registered plan.